Meeting an Unmet Need in Multiple Sclerosis
Meeting an Unmet Need in Multiple Sclerosis (MS): An Evaluation of the Effectiveness of a Transdiagnostic Psychological Treatment and Its Outcomes
We could not find results for this trial
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Unified Protocol
What it measured
Main measures
Hospital Anxiety and Depression Scale (HADS) - Change in Depression
Baseline, 12 weeks, 24 weeks
Mood and sleepHospital Anxiety and Depression Scale (HADS) - Change in Anxiety
Baseline, 12 weeks, 24 weeks
Mood and sleep
Other measures (11)
Modified Fatigue Impact Scale (MFIS) - Change in Fatigue
Baseline, 12 weeks, 24 weeks
FatiguePittsburgh Sleep Quality Index (PQSI) - Change in Sleep
Baseline, 12 weeks, 24 weeks
Mood and sleepMOS Pain Effects Scale (PES) - Change in Pain
Baseline, 12 weeks, 24 weeks
PainGeneral Self-Efficacy Scale (GSES) - Change in Self-efficacy
Baseline, 12 weeks, 24 weeks
University of Washington Self-Efficacy Scale - Change in MS specific self-efficacy
Baseline, 12 weeks, 24 weeks
University of Washington Resilience Scale - Change in Resilience
Baseline, 12 weeks, 24 weeks
COPE inventory - Change in Coping
Baseline, 12 weeks, 24 weeks
Benefit Finding in Multiple Sclerosis (BFIMS) - Change in Benefit-finding
Baseline, 12 weeks, 24 weeks
Satisfaction with Life Scale (SWLS) - Changes in Quality of Life
Baseline, 12 weeks, 24 weeks
Quality of life (reported by participants)Flourishing Scale (FS) - Change in Quality of Life
Baseline, 12 weeks, 24 weeks
Quality of life (reported by participants)
Who could take part
MS (type not specified) · 18 and over
Show the full criteria
Inclusion criteria
* Diagnosis of multiple sclerosis * 18 years of age or older * Experiencing significant depression and/or anxiety * English-speaking * Able to provide informed consent * Access to the internet
Exclusion criteria
* History of any other neurological illness (e.g. traumatic brain injury, epilepsy, dementia) * Current participation in another randomized controlled trial * Cognitive impairment that would affect my ability to fully participate in the group * Unable to attend group sessions * Active participation in another formal clinical group or psychological therapy * Any other medical or psychological condition that, in the judgement of the investigators, prevents successful participation in the study
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The primary objectives of this study is to examine the efficacy of the Unified Protocol in decreasing depression and anxiety among individuals with MS and the secondary outcomes (e.g., improved well-being, QOL, coping, etc.) that may occur in tandem.
Papers
Loading reviews and guidelines…
History
Started
Apr 2023
Main results due
Apr 2025
Finished
Apr 2026